Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis

• Published in: Journal of the Canadian Association of Gastroenterology Vol. 5; no. 1; pp. e1 - e11
• Main Authors: Song, Yi Nong, Yang, David Yi, Veldhuyzen van Zanten, Sander, Wong, Karen, McArthur, Eric, Song, Claire Zhao, Ianiro, Gianluca, Cammarota, Giovanni, Kelly, Colleen, Fischer, Monika, Russell, Lindsey, Kao, Dina
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01-02-2022
• Subjects: Original; Clostridioides difficile; Fecal microbiota transplantation
• ISSN: 2515-2084; 2515-2092
• DOI: 10.1093/jcag/gwab023

Abstract
Background
Severe or fulminant Clostridioides difficile infection (SFCDI) is associated with significant morbidity and mortality. Emerging evidence suggests fecal microbiota transplant (FMT) may be a promising therapy for SFCDI.
Aim
This systematic review determines the safety and efficacy of FMT in medically refractory SFCDI.
Methods
A systematic search of the literature was conducted using PubMed (1965 to 2020), Web of Science (1900 to 20), EMBASE (1974 to 2020), and Cochrane Review (1945 to 2020). Quality appraisal by NIH Study Quality Assessment tools, and data extraction were performed by two teams of independent researchers. The primary outcome was resolution of SFCDI 4 weeks after the final FMT. Pooled resolution rates were calculated using generalized linear mixed models estimates.
Results
Two hundred and forty patients from 10 studies (8 case series, 1 case–control and 1 randomized study) were included with 209 individual patient-level data. FMT resulted in resolution of SFCDI within 4 weeks in 211/240 individuals for a pooled estimate of 88% (95% confidence interval [CI]: 0.83 to 0.91). The mean number of FMT required was 1.6 for severe and 2.0 for fulminant CDI resolution. The pooled proportional estimates for patients requiring CDI-directed antimicrobials after FMT was 50% (95% CI: 0.06 to 0.94) for severe CDI and 67.0% (95% CI: 0.30 to 0.91) for fulminant CDI. Serious adverse event rates were low.
Conclusion
FMT appears effective in treating SFCDI patients with low adverse events, but requires multiple treatments with a significant proportion of patients requiring additional anti-CDI antibiotics to achieve resolution. The optimal route of FMT delivery remains unknown. The presence of pseudomembranous colitis may guide additional FMT or anti-CDI antibiotic treatment.